About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.40
- USD0.40
- USD0.38
- USD2.53
- -23.60%
- 11M
- 631.76k
- 551.07k
- 22M
- 0.24
- -66.90%
Stock News
yesterday
Levi's CEO Michelle Gass says strong international business helps ward off tariff impact
CNBC
yesterday
Nvidia officially gets its $4 trillion finish. Here’s what could come next.
MarketWatch
yesterday
Levi Strauss raises sales guidance, says it will absorb some tariff costs for now
CNBC
yesterday
Business class+? Delta says segmentation is coming to high-end cabins
CNBC
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
